Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions
This article was originally published in The Pink Sheet Daily
FDA tells sponsors to revise the indication for the ER/LA analgesics to highlight appropriate patient selection rather than severity of pain and orders post-marketing studies to identify a dose and duration-of-treatment associated with higher rates of abuse, misuse, addiction, overdose and death.
You may also be interested in...
Purdue says Commonwealth is trying to hold it liable for conduct FDA has authorized; citing agency's approval of long-term use of OxyContin for chronic pain, company asks court to dismiss complaint.
FDA adds a MedGuide for immediate-release opioids and shrinks their indication; the products seemed destined for an educational REMS, but is there even more the agency could do?
Draft guideline recommends limiting dosing to equivalent of 90 mg of morphine per day and limiting use to three days after acute injury.